<DOC>
	<DOCNO>NCT01961934</DOCNO>
	<brief_summary>This study investigate well Carbon Acetate PET/CT image help correctly identify recurrent tumor versus post treatment effect ( radionecrosis ) patient previously treat high grade brain glioma .</brief_summary>
	<brief_title>C11-Sodium Acetate PET/CT Imaging Evaluation Brain Glioma , Post Therapy Necrosis Pseudo-progression</brief_title>
	<detailed_description>The study design investigate effectiveness Carbon Acetate PET/CT ( AC PET ) term ability distinguish radionecrosis/pseudo-progression viable tumor patient previously treat surgery radiation high grade glioma brain tumor . Eligible patient biopsy proven high grade glioma ( WHO grade 3 4 ) status-post prior cranial irradiation tumor ; age 18 70 ; ECOG/Zubrod 0-2 , contraindication trial entry , post-irradiation cranial MRI CT demonstrate enhance lesion uncertain etiology ( biopsied ) treat least two week steroidal therapy . Responders steroidal therapy classify either pseudo-progression ( asymptomatic ) radionecrosis ( symptomatic ) . Non-responders ( respond clinically , radiographically , ) refer FDG PET/CT initial AC PET/CT within 3 week , subsequently refer stereotactic biopsy lesion follow focal laser treatment ( operative setting ) within 3 week AC PET/CT . Specific Goals/Questions : 1 . What yield ( sensitivity , accuracy , positive negative predictive value ) state-of-the-art PET/CT C-11 Acetate detect recurrent disease versus post treatment effect pseudo-progression patient population ? 2 . How performance PET C-11 Acetate compare PET use F-18 fluorodeoxyglucose ( FDG-PET ) MRI ? 3 . Evaluate optimal timing post injection imaging .</detailed_description>
	<mesh_term>Glioma</mesh_term>
	<mesh_term>Disease Progression</mesh_term>
	<mesh_term>Necrosis</mesh_term>
	<criteria>Patients age 1870 Pathologically confirm World Health Organization ( WHO ) grade 3 4 glioma ECOG/Zubrod 02 Prior external beam radiotherapy 59.460 Gray 1.82 Gy fraction Postradiotherapy contrastenhanced cranial MRI obtain least 6 week completion external beam radiotherapy show enhance anomaly ( recurrent/progressive tumor versus pseudoprogression versus radionecrosis ) Patient complete least two week course palliative steroid therapy enhance anomaly No prior designate therapy steroid presume radionecrosis recurrent tumor Patient clinical and/or radiological response steroid therapy Patient eligible stereotactic brain biopsy Patient eligible focal laser therapy Patients age 18 year Claustrophobic patient</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>70 Years</maximum_age>
	<verification_date>September 2016</verification_date>
	<keyword>glioblastoma</keyword>
	<keyword>high grade brain tumor</keyword>
	<keyword>recurrent</keyword>
	<keyword>pseudo-progression</keyword>
	<keyword>radionecrosis</keyword>
	<keyword>carbon acetate</keyword>
	<keyword>C11 aceate</keyword>
	<keyword>PET</keyword>
	<keyword>positron emission tomography</keyword>
</DOC>